Antibiotic News and Research

RSS

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.

Renhuang Pharmaceuticals' net income for first-quarter of 2010 increases 17.8%

Renhuang Pharmaceuticals, Inc., a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines, today announced its financial results for the first quarter ended January 31, 2010.

17 Mar 2010

Nasal washes may help reduce sinus infection

Washing out your nose with a spray or spout of salt water is safe and might even get you back to work sooner after a cold or acute sinus infection. However, there is not enough evidence to show that it can reduce your symptoms significantly, according to a new research review.

17 Mar 2010

IDSA calls for global commitment to develop 10 new antibiotics by 2020

As the deaths and suffering caused by antibiotic-resistant bacterial infections continue to rise around the world, the Infectious Diseases Society of America (IDSA) is urging a global commitment to develop 10 new antibiotics by 2020, known as the 10 x '20 initiative, to address this public health crisis and safeguard patients' health.

17 Mar 2010

Cytheris study: rhIL-7 treatment restores T cell trafficking and improves survival in animal model of sepsis

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced publication of data from a preclinical study in a clinically relevant animal model of sepsis showing that recombinant human Interleukin-7 (rhIL-7) treatment not only restores T cell trafficking and function, but also translates into improved survival.

16 Mar 2010

MicuRx Pharmaceuticals files IND for MRX-I antibiotic drug candidate with Chinese SFDA

MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced that it has filed an Investigational New Drug (IND) application with the State Food and Drug Administration (SFDA) in China for MRX-I, its first development-stage antibiotic drug candidate. MRX-I, an orally-administered oxazolidinone, targets multi-drug resistant Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).

15 Mar 2010

New findings may help develop potential therapies for lupus, rheumatoid arthritis and cancer

Medical Research Council (MRC) scientists at the University of Leicester have made a new advance in understanding how the body fights certain types of cancer and other disease such as Lupus and rheumatoid arthritis.

15 Mar 2010

MiddleBrook Pharmaceuticals full-year 2009 revenues rise 67.7%

MiddleBrook Pharmaceuticals, Inc. today announced its 2009 fourth quarter and full-year results, that it is further restructuring to reduce expenses, and that it is evaluating strategic alternatives to maximize shareholder value.

12 Mar 2010

Antibiotics lower risk of developing gastric cancer

Helicobacter pylori, a bacterium found in about 50% of humans worldwide, can cause stomach ulcers and, in extreme cases, gastric cancer. In an article for F1000 Medicine Reports, Seiji Shiota and Yoshio Yamaoka discuss the possible eradication of H. pylori infections

12 Mar 2010

PolyMedix presents data from PMX-30063 defensin-mimetic antibiotic compound Phase 1B study at 8th TSIS

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has presented for the first time to the medical community data from its Phase 1B clinical study with its defensin-mimetic antibiotic compound, PMX-30063.

12 Mar 2010

bioMerieux introduces FDA cleared chromID VRE for detecting Enterococcus faecium and Enterococcus faecalis

bioMerieux – a world leader in the field of in vitro diagnostics – today announced the launch of the first Food and Drug Administration (FDA) cleared chromID™ VRE, a simple and cost-effective solution in the struggle against vancomycin-resistant enterococci (VRE). chromID VRE is the first to receive an FDA 510(k) clearance for the qualitative detection of Enterococcus faecium and Enterococcus faecalis showing acquired resistance to vancomycin in stool specimens.

12 Mar 2010

FDA provides guidance on Restanza clinical program in treatment of CABP

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, announced today that the U.S. Food and Drug Administration has provided guidance on the clinical program required to assess the approvability of Restanza™ (cethromycin), a novel oral once-a-day antibiotic, in the treatment of outpatient community acquired bacterial pneumonia (CABP) as well as biodefense indications including anthrax, plague and tularemia.

11 Mar 2010

Advanced Life Sciences Holdings reports decrease in net loss for full-year 2009

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced its financial results for the fourth quarter and full year ended December 31, 2009.

11 Mar 2010

Ampicillin activates torsinA, improves cell function to reduce movement disorders

Discovery of an antibiotic's capacity to improve cell function in laboratory tests is providing movement disorder researchers with leads to more desirable molecules with potentially similar traits, according to University of Alabama scientists co-authoring a paper publishing March 10 in the journal Disease Models & Mechanisms.

11 Mar 2010

FDA clears Oculus Innovative Sciences' Microcyn Skin and Wound HydroGel

Oculus Innovative Sciences, Inc., a commercial medical technology company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, today announced that it has received new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for new dermatology indications for Microcyn® Skin and Wound HydroGel.

10 Mar 2010

Accelr8 Technology to present results of culture-free, quantitative pathogen identification study at 110th ASM

Accelr8 Technology Corporation today announced that it has received acceptance to present results for a study on 2-hour, culture-free, quantitative pathogen identification. The study was co-authored with principal investigators at the Denver Health Medical Center and the Barnes-Jewish Hospital in St. Louis.

10 Mar 2010

Cempra Pharmaceuticals completes Phase 1 clinical trials of CEM-101 macrolide

Cempra Pharmaceuticals today announced the successful completion of Phase 1 clinical trials of its oral formulation of CEM-101, which showed good tolerability in those studies. The company also announced plans to submit an IND to the FDA to begin a Phase 1 study with the company's intravenous formulation of CEM-101 in mid-2010.

10 Mar 2010

Inadvertent exposure of hospital housekeepers to drug-resistant "Superbugs" may lead to hospital-infection epidemic

One cause of the rampant international hospital-infection epidemic may be the "inadvertent exposure" of hospital housekeepers and transporters to antibiotic-resistant "Superbugs" such as MRSA, says TeleTracking Technologies CEO Anthony Sanzo.

10 Mar 2010

MicroPhage seeks FDA clearance for MRSA/MSSA Blood Culture Test, submits clinical study data

MicroPhage announced that it has submitted human data from a pivotal clinical study of its ‘Microphage MRSA/MSSA Blood Culture Test’ to support a U.S. Food and Drug Administration (FDA) 510(k) premarket notification process. The first of MicroPhage’s instrument-free, rapid tests is based on the Company’s patented Bacteriophage Amplification platform technology. MicroPhage further announced that it has already begun OUS commercial shipments of the test.

5 Mar 2010

China Pharma Holdings reports 21% increase in 2009 revenue

China Pharma Holdings, Inc., which develops, manufactures, and markets specialty pharmaceutical products in China, today announced financial results for the fiscal year ended December 31, 2009.

5 Mar 2010

Common allergens that may cause contact dermatitis

Itchy irritated skin can leave some people scratching their heads trying to determine the cause of this bothersome condition. What did they touch? Is it just dry skin gone awry? Are they allergic to something in their home or workplace? The answers to these questions could require not only a little detective work, but the help of a dermatologist who can diagnose and treat the most likely culprit - contact dermatitis.

5 Mar 2010

Antibiotic News and Research

Further Reading

Renhuang Pharmaceuticals' net income for first-quarter of 2010 increases 17.8%

Nasal washes may help reduce sinus infection

IDSA calls for global commitment to develop 10 new antibiotics by 2020

Cytheris study: rhIL-7 treatment restores T cell trafficking and improves survival in animal model of sepsis

MicuRx Pharmaceuticals files IND for MRX-I antibiotic drug candidate with Chinese SFDA

New findings may help develop potential therapies for lupus, rheumatoid arthritis and cancer

MiddleBrook Pharmaceuticals full-year 2009 revenues rise 67.7%

Antibiotics lower risk of developing gastric cancer

PolyMedix presents data from PMX-30063 defensin-mimetic antibiotic compound Phase 1B study at 8th TSIS

bioMerieux introduces FDA cleared chromID VRE for detecting Enterococcus faecium and Enterococcus faecalis

FDA provides guidance on Restanza clinical program in treatment of CABP

Advanced Life Sciences Holdings reports decrease in net loss for full-year 2009

Ampicillin activates torsinA, improves cell function to reduce movement disorders

FDA clears Oculus Innovative Sciences' Microcyn Skin and Wound HydroGel

Accelr8 Technology to present results of culture-free, quantitative pathogen identification study at 110th ASM

Cempra Pharmaceuticals completes Phase 1 clinical trials of CEM-101 macrolide

Inadvertent exposure of hospital housekeepers to drug-resistant "Superbugs" may lead to hospital-infection epidemic

MicroPhage seeks FDA clearance for MRSA/MSSA Blood Culture Test, submits clinical study data

China Pharma Holdings reports 21% increase in 2009 revenue

Common allergens that may cause contact dermatitis

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News